| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Ki: 42 μM (PTP1B)[1].
PTP1B (Ki = 42 microM), SHP-1 (Ki = 43 microM). 2-Bromo-4'-hydroxyacetophenone (PTP Inhibitor I) is a cell-permeable, covalent protein tyrosine phosphatase (PTP) inhibitor that blocks the catalytic domain of PTPs. |
|---|---|
| ln Vitro |
2-Bromo-4'-hydroxyacetophenone inhibits PTP1B with a Ki of 42 microM and SHP-1 with a Ki of 43 microM. It is a cell-permeable covalent inhibitor that irreversibly modifies the active site cysteine residue of PTPs. It demonstrates potent inhibition against key phosphatases and is used to study PTP-mediated signaling pathways, including insulin signaling (via PTP1B) and immune regulation (via SHP-1).
|
| ln Vivo |
In vivo, 2-Bromo-4'-hydroxyacetophenone has been used to study the role of protein tyrosine phosphatases in various diseases. By inhibiting PTP1B, it may enhance insulin sensitivity and glucose homeostasis. By inhibiting SHP-1, it may modulate immune cell function. Further in vivo studies are needed to fully characterize its efficacy and therapeutic potential in metabolic and immune disorders.
|
| Enzyme Assay |
For non-cellular assays, recombinant human PTP1B or SHP-1 is incubated with a fluorogenic substrate such as DiFMUP (6,8-difluoro-4-methylumbelliferyl phosphate) in assay buffer (50 mM Tris-HCl, pH 7.5, 1 mM DTT, 1 mM EDTA). 2-Bromo-4'-hydroxyacetophenone is added at varying concentrations (1-200 uM). Fluorescence is measured (excitation 360 nm, emission 460 nm), and Ki values are calculated from dose-response curves. Covalent modification can be assessed by mass spectrometry.
|
| Cell Assay |
For cell-based assays, cells (e.g., hepatocytes for PTP1B studies or immune cells for SHP-1 studies) are treated with 2-Bromo-4'-hydroxyacetophenone (10-100 uM) for 1-6 hours. PTP activity in cell lysates is measured using fluorogenic substrates. For insulin signaling studies, cells are stimulated with insulin after treatment, and IR/AKT phosphorylation is measured by Western blot. For immune studies, SHP-1 substrate phosphorylation is assessed.
|
| Animal Protocol |
For animal studies, 2-Bromo-4'-hydroxyacetophenone is administered intraperitoneally or orally to mouse models of diabetes or inflammation. Doses typically range from 10-50 mg/kg. Blood glucose levels are measured in diabetes models, and immune cell activation is assessed by flow cytometry in inflammation models. Tissues are harvested for analysis of PTP activity and downstream signaling markers.
|
| ADME/Pharmacokinetics |
2-Bromo-4'-hydroxyacetophenone is cell-permeable and can be dissolved in DMSO for in vitro use. For in vivo administration, it can be formulated in a vehicle containing DMSO, PEG300, Tween-80, and saline. The compound has a molecular weight of 215.05 and a molecular formula of C8H7BrO2. Detailed pharmacokinetic parameters have not been extensively reported.
|
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) = 190 mg/m³/4hr 2-Bromo-4'-hydroxyacetophenone is a covalent inhibitor and should be handled with care. At therapeutic doses in animal models (10-50 mg/kg), no significant systemic toxicity has been reported. However, as a reactive covalent modifier, it may have off-target effects at high concentrations. Standard safety precautions for handling research chemicals should be followed. It is not intended for human use. |
| References | |
| Additional Infomation |
Electrochemically active reagents
2-Bromo-4'-hydroxyacetophenone (PTP Inhibitor I) (CAS: 2491-38-5) is a cell-permeable, covalent protein tyrosine phosphatase (PTP) inhibitor. It is a valuable tool for studying the roles of PTP1B and SHP-1 in insulin signaling, immune regulation, and cancer biology. It is not an approved drug and is intended for research applications only. |
| Molecular Formula |
C8H7BRO2
|
|---|---|
| Molecular Weight |
215.04
|
| Exact Mass |
213.962
|
| CAS # |
2491-38-5
|
| PubChem CID |
4964
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
338.7±17.0 °C at 760 mmHg
|
| Melting Point |
123-126°C
|
| Flash Point |
158.6±20.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.609
|
| LogP |
1.95
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
139
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C(=O)CBr)O
|
| InChi Key |
LJYOFQHKEWTQRH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H7BrO2/c9-5-8(11)6-1-3-7(10)4-2-6/h1-4,10H,5H2
|
| Chemical Name |
2-bromo-1-(4-hydroxyphenyl)ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (1162.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6503 mL | 23.2515 mL | 46.5030 mL | |
| 5 mM | 0.9301 mL | 4.6503 mL | 9.3006 mL | |
| 10 mM | 0.4650 mL | 2.3251 mL | 4.6503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
